US20080154339A1 - Electrically Nonconductive Occludent For Tissue Openings - Google Patents

Electrically Nonconductive Occludent For Tissue Openings Download PDF

Info

Publication number
US20080154339A1
US20080154339A1 US11/614,851 US61485106A US2008154339A1 US 20080154339 A1 US20080154339 A1 US 20080154339A1 US 61485106 A US61485106 A US 61485106A US 2008154339 A1 US2008154339 A1 US 2008154339A1
Authority
US
United States
Prior art keywords
occludent
cochleostomy
carrier member
cochlea
cochlear implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/614,851
Inventor
Paul M. Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cochlear Ltd
Original Assignee
Cochlear Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cochlear Ltd filed Critical Cochlear Ltd
Priority to US11/614,851 priority Critical patent/US20080154339A1/en
Assigned to COCHLEAR LIMITED reassignment COCHLEAR LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CARTER, PAUL M.
Publication of US20080154339A1 publication Critical patent/US20080154339A1/en
Priority to US13/303,631 priority patent/US9345876B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/0526Head electrodes
    • A61N1/0541Cochlear electrodes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F11/00Methods or devices for treatment of the ears or hearing sense; Non-electric hearing aids; Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense; Protective devices for the ears, carried on the body or in the hand
    • A61F11/04Methods or devices for enabling ear patients to achieve auditory perception through physiological senses other than hearing sense, e.g. through the touch sense
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/18Internal ear or nose parts, e.g. ear-drums
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode

Definitions

  • the present invention relates generally to cochlear implant devices, and more particularly, to an electrically nonconductive cochleostomy occludent.
  • Hearing loss is generally of two types, namely conductive and sensorineural.
  • the treatment of both of types of hearing loss has been quite different, relying on different principles to deliver sound signals to be perceived by the brain as sound.
  • Conductive hearing loss occurs when the normal mechanical pathways for sound to reach the hair cells in the cochlea are impeded, for example, by damage to the ossicles.
  • hearing loss is often improved with the use of conventional hearing aids, which amplify the sound so that acoustic information reaches the cochlear hair cells.
  • Such hearing aids utilize acoustic mechanical stimulation, whereby the sound is amplified according to a number of varying techniques, and delivered to the inner ear as mechanical energy. This may be through a column of air to the eardrum, or through direct delivery to the ossicles of the middle ear.
  • sensorineural hearing loss is due to the absence or destruction of the cochlear hair cells which are needed to transduce acoustic signals into auditory nerve impulses.
  • Individuals suffering from this type of hearing loss are unable to derive any benefit from conventional hearing aid systems regardless of the volume of the acoustic stimulus. This is because the natural mechanisms for transducing sound energy into auditory nerve impulses are either absent or damaged.
  • cochlearTM implants also referred to as cochlearTM devices, cochlearTM prostheses, cochlearTM implant systems, and the like; simply “cochlear implants” herein
  • cochlearTM implants have been developed to provide the sensation of hearing to such individuals.
  • electrical stimulation is provided via stimulating electrodes positioned as close as possible to the nerve endings of the auditory nerve, essentially bypassing the hair cells in a normally functioning cochlea.
  • the application of a stimulation pattern to the nerve endings causes impulses to be sent to the brain via the auditory nerve, resulting in the brain perceiving the impulses as sound.
  • the electrode array is inserted during an operation that usually takes between 2-3 hours depending on the device to be implanted.
  • An incision is made behind the ear to expose the temporal bone; the temporal bone consists of the squamous, the mastoid, the tympanic, zygomatic and petrous segment.
  • cochlear implants require the opening of the mastoid bone which leads to the middle ear.
  • a shallow recess is then created to hold the implant package in place substantially level with the bone.
  • a hole is drilled which allows the surgeon access into the cochlea. This hole is known as a cochleostomy—the opening from the middle ear to the perilymphatic canals of the cochlea.
  • a cochleostomy may be formed through the round window 141 , the oval window 110 , the promontory or through the apical turn of the cochlea.
  • the electrode array is then gently threaded into the shell-like structure of the cochlea and the incision closed; the cochleostomy remains open and heals with scar tissue over the next few days.
  • an electrically nonconductive occludent id disclosed, the occludent constructed and arranged to forcefully infill a tissue opening so as to effectively prevent transport of electrical current, fluid and bacteria through the tissue opening.
  • a cochlear implant comprising: an elongate electrode carrier member having at least one electrode disposed thereon, wherein the carrier member is configured to traverse a cochleostomy to position the electrodes in the cochlea; and an electrically nonconductive occludent constructed and arranged to circumferentially surround a portion of the carrier member traversing the cochleostomy, and to forcefully infill cochleostomy thereby segregating perilymphatic canals of the cochlea from extracochlear regions.
  • a method for implanting an elongate carrier member in a cochlea of a recipient comprising: creating a cochleostomy; implanting the carrier member into the cochlea; and positioning an electrically nonconductive occludent in the cochleostomy so as to cause the portion of the carrier member and the occludent to forcefully infill the cochleostomy.
  • FIG. 1 is a perspective view of an example of an implanted cochlear implant suitable for implementing embodiments of the present invention
  • FIG. 2A is a side view of an electrode assembly in accordance with one embodiment of the present invention.
  • FIG. 2B is a top view of the electrode assembly illustrated in FIG. 2A ;
  • FIG. 3 is a schematic diagram of the cochlea showing a conventional intra-cochlear electrode insertion with the cochleostomy sealed using muscle/fat tissue;
  • FIG. 4 is a cross-sectional view of a portion of a cochlea showing an improved cochleostomy seal in accordance with one embodiment of the present invention
  • FIG. 5 is a perspective view of one embodiment of the electrically nonconductive occludent of the present invention.
  • FIG. 6 is a perspective view of a human cochlea showing the embodiment of the occludent illustrated in FIG. 5 implanted in a cochleostomy, in accordance with embodiments of the present invention.
  • FIG. 7 is a cross-sectional view of an alternative embodiment of a cochleostomy occludent of the present invention.
  • the present invention is generally directed to an electrically nonconductive occludent that forcefully infills and seals a cochleostomy or other tissue opening with or without an implantable component traversing the tissue opening.
  • an embodiment of the electrically nonconductive occludent is utilized to seal a cochleostomy having an implanted electrode assembly traversing therethrough, or other tissue opening such as the oval or round window with no such implanted component, thereby segregating the perilymphatic canals of the cochlea from extracochlear regions such as the middle ear.
  • the occludent has a toroidal cross-sectional shape, circumferentially surrounding the implanted component such as an electrode carrier member.
  • the occludent may have a combination of one or more characteristics such as shape and durometer to partially enter the cochleostomy and to consume substantially all space between the carrier member and cochlea at the cochleostomy.
  • the occludent may be permanently positioned on the carrier member, or it may be configured to slide over the carrier member to be positioned at the occluding position.
  • the occludent is configured to travel through the carrier member lumen to the occluding position.
  • Such embodiments of the occludent may be configured to travel over the stylet used to implant the carrier member, or may be configured to be inserted with a tool for subsequent expansion.
  • the occludent may be a mechanical structure that is inflated mechanically or with a balloon.
  • the present invention provides a high electrical impedance blockage within the cochleostomy, thereby reducing the electric charge which may travel from the electrodes to, for example, an extracochlear reference electrode of the cochlear implant.
  • the present invention is operable regardless of the relative size and location of the cochleostomy and carrier member regardless of whether the cochleostomy is formed through round window 141 , the oval window 110 , the promontory, the apical turn of the cochlea, or at any other therapeutically beneficial location to operatively reduce current flow through a tissue opening and thereby improve the electrical efficiency of the implant.
  • openings other than a cochleostomy may be made to accommodate the requirements of other types of prosthetic hearing implants.
  • tissue openings there are also circumstances that it is desirable to seal round window 141 and/or oval window 110 due to natural conditions, prior surgical procedure, etc.
  • Such openings in tissue, whether they form naturally or occur due to disease, injury or surgery, are collectively and generally referred to herein as a tissue opening.
  • the present invention may be implemented in a variety of ways and the embodiments illustrated are to be considered only as illustrative constructions. More particularly, the present invention is potentially useful for purposes other than sealing a cochleostomy created as described herein.
  • the present invention may be applied to seal an existing orifice between the middle ear and the inner ear such as round window 141 .
  • the present invention may be used to seal any opening created between the middle ear and the perilymph, whether this is intended to be used as a conduit for a part of an implanted device, or to be sealed completely after surgery.
  • cochleostomy should accordingly be understood for the purposes of this application in this expansive sense.
  • Such sealing may have further advantages, for example reducing the chance of the recipient contracting meningitis. It may also reduce the risk of unintended explantation.
  • the present invention accordingly allows current leakage via the cochleostomy of a hearing implant prosthesis to be reduced. As a consequence, the current levels used for stimulation can be decreased as the implant's energy is used more efficiently.
  • Embodiments of the present invention are described below in connection with one type of stimulating medical device having an component implantable through a tissue opening; that is, a prosthetic hearing implant and, more specifically, a cochlear implant.
  • Cochlear implants use direct electrical stimulation of auditory nerve cells to bypass absent or defective hair cells that normally transduce acoustic vibrations into neural activity.
  • Such devices generally use multi-contact electrodes inserted into the scala tympani of the cochlea so that the electrodes may differentially activate auditory neurons that normally encode differential pitches of sound.
  • Such devices are also used to treat a smaller number of patients with bilateral degeneration of the auditory nerve.
  • the cochlear implant provides stimulation of the cochlear nucleus in the brainstem.
  • Such devices therefore, are commonly referred to as auditory brainstem implants (ABIs).
  • Exemplary embodiments of a cochlear implant include a ContourTM, FreedomTM, NucleusTM or CochlearTM implant sold by Cochlear Limited, Australia. Such devices are described in U.S. Pat. Nos. 4,532,930, 6,537,200, 6,565,503, 6,575,894, and 6,697,674, the entire contents and disclosures of which are hereby incorporated by reference herein. It should be understood to those of ordinary skill in the art that embodiments of the present invention may be used in other stimulating medical devices such as neurostimulators, cardiac pacemakers/defibrillators, etc. as well as other medical devices which utilize an elongate carrier member to temporarily or permanently implant, deliver or otherwise introduce a therapeutic agent, sensor, device, etc. into a recipient.
  • stimulating medical devices such as neurostimulators, cardiac pacemakers/defibrillators, etc.
  • other medical devices which utilize an elongate carrier member to temporarily or permanently implant, deliver or otherwise introduce a therapeutic agent, sensor, device, etc. into
  • FIG. 1 is a cut-away view of the relevant components of outer ear 101 , middle ear 102 and inner ear 103 , which are described next below.
  • outer ear 101 comprises an auricle 105 and an ear canal 106 .
  • An acoustic pressure or sound wave 107 is collected by auricle 105 and channeled into and through ear canal 106 .
  • Disposed across the distal end of ear cannel 106 is a tympanic membrane 104 which vibrates in response to acoustic wave 107 . This vibration is coupled to oval window, or fenestra ovalis, 110 through three bones of middle ear 102 , collectively referred to as the ossicles 111 .
  • Ossicles 111 comprises the malleus 112 , the incus 113 and the stapes 114 .
  • Bones 112 , 113 and 114 of middle ear 102 serve to filter and amplify acoustic wave 107 , causing oval window 110 to articulate, or vibrate.
  • Such vibration sets up waves of fluid motion within cochlea 115 .
  • Such fluid motion activates tiny hair cells (not shown) that line the inside of cochlea 115 .
  • Activation of the hair cells causes appropriate nerve impulses to be transferred through the spiral ganglion cells (not shown) to auditory nerve 116 and, ultimately, to the brain where they are perceived as sound.
  • Cochlear implant 120 is utilized to directly stimulate the ganglion cells to provide a hearing sensation to such persons.
  • FIG. 1 also shows how cochlear implant 120 is positioned in relation to outer ear 101 , middle ear 102 and inner ear 103 .
  • Cochlear implant 120 comprises external component assembly 122 which is directly or indirectly attached to the body of the recipient, and an internal component assembly 124 which is temporarily or permanently implanted in the recipient.
  • External assembly 122 comprises microphone 125 for detecting sound which is provided to a behind-the-ear (BTE) speech processing unit 126 that generates coded signals.
  • BTE behind-the-ear
  • the coded signals are provided to an external transmitter unit 128 , along with power from a power source (not shown) such as a battery.
  • External transmitter unit 128 comprises an external coil 130 and, preferably, a magnet (not shown) secured directly or indirectly in external coil 130 .
  • Internal component assembly 124 comprises an internal receiver unit 132 having an internal coil (not shown) that transcutaneously receives power and coded signals from external assembly 122 , and provides such signals to a stimulator unit 134 .
  • stimulator 134 applies stimulation signals to cochlea 115 via an implanted electrode assembly 140 .
  • Electrode assembly 140 enters cochlea 115 via a cochleostomy 142 , and has an array 144 of one or more electrodes 150 positioned to be substantially aligned with portions of tonotopically-mapped cochlea 115 .
  • the delivery of stimulation signals at various locations along cochlea 115 causes a hearing percept representative of the received sound 107 .
  • cochlear implant 120 is described as having external components, in another embodiment, the controller, including the microphone, speech processor and power supply, may also be implantable. In such embodiments, the controller may be contained within a hermetically sealed housing or the housing used for stimulator unit 134 .
  • Electrode assembly 140 preferably assumes an optimal electrode position in cochlea 115 upon or immediately following implantation into the cochlea. It is also desirable that electrode assembly 140 be configured such that the insertion process causes minimal trauma to the sensitive structures of cochlea 115 . Usually electrode assembly 140 is pre-curved, held in a straight configuration at least during the initial stages of the implantation procedure, conforming to the natural shape of the cochlea during and subsequent to implantation.
  • FIG. 2A is a side view of an embodiment of electrode assembly 140 , referred to herein as electrode assembly 200 .
  • FIG. 2B is a top view of electrode assembly 200 .
  • Electrode assembly 200 comprises a carrier member 202 , a stop member 204 and lead 206 .
  • Carrier member 202 has a distal end 208 adapted to be implanted furthest into cochlea 115 , and a proximal end 210 connected to a distal end 214 of laterally-extending stop member 204 .
  • the opposing proximal end 216 of stop member 204 is connected to lead 206 .
  • Lead 206 physically and electrically connects electrode assembly 200 with stimulator unit 134 .
  • the surface of carrier member 202 which faces the interior of cochlea 115 is referred to herein as the medial surface 216 of carrier member 202 .
  • the opposing side of carrier member 202 referred to herein as lateral surface 218 , faces the external wall and bony capsule (not shown) of cochlea 115 .
  • medial surface, medial direction, and the like are generally used herein to refer to the surfaces, features and directions toward the center of cochlea 115
  • lateral surface, lateral direction, and the like are generally used herein to refer to surfaces, features and directions toward the exterior of cochlea 115 .
  • a longitudinal axis 250 is utilized herein to facilitate descriptions herein.
  • Electrodes 212 are mounted on or in carrier member 202 . Electrodes 212 may be disposed in a linear or non-linear array on or in carrier member 202 , and may be positioned to align with predetermined regions of tonotopically mapped cochlea 115 . In alternative embodiments, electrodes 212 are implemented as described in U.S. Provisional Patent Application No. 60/748,217, 60/748,273 and 60/748,314, hereby incorporated by reference herein.
  • FIG. 3 is a schematic of cochlear 115 showing a conventional, intra-cochlear electrode insertion, where cochleostomy 142 is sealed using a graft 302 of the recipient's tissue, typically muscle and fat.
  • cochleostomy 142 is shown in an exterior wall 304 of cochlea 115 , and is situated in the space of middle ear 102 .
  • Graft 302 is positioned around carrier member 140 over cochleostomy 142 , as shown in FIG. 3 .
  • FIG. 4 is a cross-sectional view of a portion of a cochlea showing an improved cochleostomy seal in accordance with one embodiment of the present invention.
  • a deformable electrically nonconductive occludent 400 is inserted into cochleostomy 142 to prevent the transfer of fluids, bacteria and electrical current through cochleostomy 142 .
  • occludent 400 is formed from a soft, deformable grade of silicone elastomer. Such combination of characteristics allows occludent 400 to elastically conform to the generally irregular shape of cochleostomy 142 .
  • Occludent 400 may be formed around elongate electrode carrier member 140 so that it can slide along the carrier member.
  • occludent 400 has an aperture suitable for slidingly receiving the implantable component that is to be traversing through the tissue opening, here carrier member 140 traversing cochleostomy 142 .
  • the surgeon would insert electrode carrier member 140 through cochleostomy 142 and into cochlea 115 in a conventional manner.
  • This process is well understood in the art, and described in the literature, and conventional aspects of this process will not be further described in detail.
  • a standard reference for such a process is described in “Surgical Techniques for Cochlear Implants”, Noel L. Cohen, Chapter 8, p 151 in “Cochlear Implants”, Waltzman, S. B. and Cohen, L. L. (1997) ISBN 0-86577-882-5, the disclosure of which is hereby incorporated by reference.
  • the extent of insertion will vary significantly from recipient to recipient, depending upon the peculiarities of the anatomy of the recipient, the specific surgical procedure used by the surgeon, and the precise location of cochleostomy 142 . It is expected that the most improvement in leakage reduction will be for the basal electrodes 150 , as these electrodes have the shortest leakage path. It therefore also follows that greater improvement may be seen in short or partial electrode arrays, for example as used in electro-acoustic stimulation.
  • occludent 400 may be slid along electrode carrier member 140 to be partially inside cochlea 115 and partially outside cochlea 115 ; that ins occludent 400 infills cochleostomy 142 . Because this embodiment of occludent 400 has an exterior radius that is larger than the interior radius of cochleostomy 142 , and because occludent 400 is malleable; that is, has a low durometer, it deforms to partially enter cochlea 115 thereby forcefully infilling cochleostomy 142 so as to effectively prevent transport of electrical current, fluid and bacteria through the cochleostomy.
  • occludent 400 fills the available space between the walls of cochlea 115 defining cochleostomy 142 and the exterior of carrier member 140 which passes through the cochleostomy. Furthermore, occludent 400 sufficiently infills cochleostomy 142 so that fluids, bacteria, etc., cannot pass through an remaining apertures between cochlea 115 and occludent 400 . Thus, occludent 400 provides a seal of electrically nonconductive, or insulating, biocompatible material within cochleostomy 142 .
  • Occludent 400 thereby increases the impedance of the undesired current path through cochleostomy 142 to the reference electrode (not shown) of cochlear implant 120 located outside the inner ear 103 . It should be appreciated to those of ordinary skill in the art that as the anatomical structures surrounding occludent 400 are partially conductive and, as such, electric current may still leak through this general region, but current leakage through cochleostomy 142 will be reduced.
  • occludent 400 shown in FIG. 4 is generally toroidal in shape, as it surrounds electrode carrier member 140 and infills cochleostomy 142 as described above.
  • any other suitable shape may be used.
  • One such suitable shape is a truncated cone 500 , as shown in FIGS. 5 and 6 .
  • FIG. 5 is a perspective view of an occludent 500 having a truncated cone configuration
  • FIG. 6 is a perspective view of occludent 500 inserted into cochleostomy 142 of cochlea 115 .
  • truncated cone occludent 500 which is has a smaller diameter is dimensioned to easily pass through cochleostomy 142 to enable occludent 500 to enter cochlea 115 .
  • the end 508 of occludent 500 which is has a relatively greater diameter is dimensioned to no pass through cochleostomy 142 .
  • occludent 500 forcefully infills cochleostomy 142 as it is inserted into the cochleostomy, thereby sealing cochlea 115 .
  • body 506 of occludent 500 is also malleable to enable the occludent to deform in response to the forced insertion of the occludent, further insuring a forceful infilling sufficient to seal cochleostomy 142 .
  • base 508 of occludent 500 remains on the outside of cochleostomy 142 , allowing for easy removal should that be necessary.
  • occludent 500 may be implemented as an integrated or unitary element of electrode carrier member 140 , or it may be a separately manufactured component that has a channel 502 dimmensioned to slide over carrier member 140 . In either embodiment, once electrode carrier member 140 is in a suitable position and occludent 500 is in the occluding position; that is, partially infilling cochleostomy 142 , occludent 400 seals cochleostomy 142 .
  • Occludent 500 may be formed of any suitable inert biocompatible material that is operatively an electrical insulator.
  • occludent 500 is preferably formed of silicone. It should be appreciated, however, that occludent 500 may be formed of different materials or from a combination of one or more other material. It could be partly formed from a more stiff material, with the outer portions being resilient in order to provide the necessary conformable seal.
  • Occludent 500 may be formed from a suitable polymer putty material in situ. It could be formed, with a slit or the like, to allow it to be attached around the electrode carrier member 140 after insertion. Importantly, occludent 500 is formed of an insulating material and substantially seal cochleostomy 142 so as increase the impedance of the leakage path. If different shapes or forms of electrode carrier member 140 are used, then the shape of the occludent 500 will need to be adapted to suit the shape of the implanted carrier member which traverses cochleostomy 142 .
  • carrier member 140 is radially distensible and has a longitudinally-extending lumen 706 .
  • lumen 706 is configured to receive a stylet as is conventionally utilized in certain pre-curved electrode carrier members.
  • lumen 706 is configured to interoperate with occludent 700 as described herein.
  • Occludent 700 is configured to be slidingly passed through lumen 706 as shown in FIG. 7 .
  • the exterior dimensions of occludent 700 are larger than the interior dimensions of lumen 706 .
  • occludent 700 applied a force radially outward in that region of carrier member 702 in which occludent 700 is located. Because carrier member 702 is outwardly distensible, such force causes carrier member 702 to dilate or expand in the region containing occludent 700 , as shown in FIG. 7 .
  • advancing occludent 700 to be partially inside cochlea 115 causes carrier member 702 to expand to abut the perimeter of cochlea 115 that defines cochleostomy 142 .
  • Occludent 700 may take on any form necessary. In the embodiment shown in FIG. 7 , occludent 700 is solid. Alternatively occludent 700 may be hollow. In the embodiment shown in FIG. 7 , occludent 700 is distally tapered and has round edges. This is ti avoid damage to in interior surfaces of carrier member 702 defining lumen 706 . it should be appreciated, however, that occludent 700 may take on other shapes in alternative embodiments.
  • occludent 700 is initially located near a proximal end of electrode carrier member 702 so that it does not interfere with the normal insertion of the carrier member. After insertion of electrode carrier member 702 , occludent 700 is slid along lumen 706 to cochleostomy 142 where it deforms the sides of carrier member 702 sufficiently to seal the cochleostomy 142 .
  • This embodiment has the further advantage in that two separate components do not abut to create a potential space, thereby reducing the risk of infection.
  • a guide wire 704 is provided, and occludent 700 has an aperture for sliding receiving the guide wire 704 .
  • occludent 700 may be detachably secured to the distal end of a tool that may be advance into lumen 706 .
  • occludent 700 may be formed by being moulded as part of the electrode moulding process, at an appropriate location along the length of electrode carrier member 702 . In such embodiments, implantation of electrode carrier member 702 is performed until occludent 700 is positioned in cochleostomy 142 .
  • Such an embodiment has the same advantage as the sliding space filling plug of FIG. 7 in that it has no separate insulator parts abutting and therefore has a reduced risk of infection. It also has the advantage of not requiring a small device to be moved, relative to the array, in the confined space and delicate structures of the inner ear during implantation.
  • occludent 700 may be initially of smaller dimensions whan advanced through lumen 706 , and then expanded to a larger size to effect the radial distension of carrier member 702 noted above.
  • Such an expansion may be achieved in many ways now or later developed, such as by implementing mechanically expandable members, a material that expands in response to the pumping of air or other fluid, the mixing of materials, and the like.
  • the occludent of the present invention may be specifically shaped to fit an actual aperture, for example the oval window. Alternatively, it could be formed in situ, for example by a fast curing sealant injected around the cochleostomy 142 . Any effective artificial seal which can be positioned as required may be used to implement the invention.
  • EABR Monopolar Electrical Auditory Brainstem Response
  • Otoform paste is a settable silicone material, used in hearing aid fitting and similar applications, which is initially mouldable but which then sets to a soft deformable consistency.
  • the smallest EABR threshold (otoform putty) was about 40% smaller than the largest threshold (large muscle).
  • the impedance results varied by around 20-35% from smallest to largest.
  • the current flow through the cochleostomy varied from 84% of total current (large muscle) to 70% (otoform putty).
  • any T and C decrease gained from using the plug will manifest itself as a decrease in power consumption of the implant and a subsequent increase in battery life.
  • Power consumption of the implant can be divided into two parts—power consumed to run the implant electronics (W E ) and power consumed to deliver current to the auditory nerve (W N ).
  • the decrease in T/C level current will manifest itself as a proportional decrease in W N .
  • the ratio of W N to W E is about 50:50 for high rate strategies. If, for example, it is assumed that the plug provides a 10% decrease in T/C level this would translate to about a 5% decrease in overall implant power consumption for high rate strategies, less for lower rate strategies. However, the most recent tests show that the plug yields an improvement of between 20-40% decrease in T/C level, indicating at lease a 10% improvement in power consumption.
  • tissue openings between cochlea 115 and middle ear 102 may pass similar electric current and that may also provide similar benefit by being sealed with an embodiment of the electrically nonconductive occludent of the present invention.
  • These include round window 141 and oval window 110 .
  • Embodiments of the electrically nonconductive occludent of the present invention which are not integrated in or unitary with a carrier member may be inserted into these other tissue openings, providing a further decrease in stray electrical current.
  • the present invention may also be applied to seal a cochleostomy which is not intended to remain open, for example in some form of totally implanted device which does not require a physical conduit to remain out of inner ear 103 .

Abstract

An electrically nonconductive occludent constructed and arranged to forcefully infill a tissue opening so as to effectively prevent transport of electrical current, fluid and bacteria through the tissue opening. A cochlear implant comprising: an elongate electrode carrier member having at least one electrode disposed thereon, wherein the carrier member is configured to traverse a cochleostomy to position the electrodes in the cochlea; and an electrically nonconductive occludent constructed and arranged to circumferentially surround a portion of the carrier member traversing the cochleostomy, and to forcefully infill cochleostomy thereby segregating perilymphatic canals of the cochlea from extracochlear regions.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims priority from Australian Provisional Patent Application No. 2005907188, entitled, “Improved Cochleostomy Sealing” which was filed on Dec. 21, 2005.
  • BACKGROUND
  • 1. Field of the Invention
  • The present invention relates generally to cochlear implant devices, and more particularly, to an electrically nonconductive cochleostomy occludent.
  • 2. Related Art
  • Hearing loss is generally of two types, namely conductive and sensorineural. The treatment of both of types of hearing loss has been quite different, relying on different principles to deliver sound signals to be perceived by the brain as sound. Conductive hearing loss occurs when the normal mechanical pathways for sound to reach the hair cells in the cochlea are impeded, for example, by damage to the ossicles. In such cases, hearing loss is often improved with the use of conventional hearing aids, which amplify the sound so that acoustic information reaches the cochlear hair cells. Such hearing aids utilize acoustic mechanical stimulation, whereby the sound is amplified according to a number of varying techniques, and delivered to the inner ear as mechanical energy. This may be through a column of air to the eardrum, or through direct delivery to the ossicles of the middle ear.
  • On the other hand, sensorineural hearing loss is due to the absence or destruction of the cochlear hair cells which are needed to transduce acoustic signals into auditory nerve impulses. Individuals suffering from this type of hearing loss are unable to derive any benefit from conventional hearing aid systems regardless of the volume of the acoustic stimulus. This is because the natural mechanisms for transducing sound energy into auditory nerve impulses are either absent or damaged. In such cases, cochlear™ implants (also referred to as cochlear™ devices, cochlear™ prostheses, cochlear™ implant systems, and the like; simply “cochlear implants” herein) have been developed to provide the sensation of hearing to such individuals. In cochlear implants, electrical stimulation is provided via stimulating electrodes positioned as close as possible to the nerve endings of the auditory nerve, essentially bypassing the hair cells in a normally functioning cochlea. The application of a stimulation pattern to the nerve endings causes impulses to be sent to the brain via the auditory nerve, resulting in the brain perceiving the impulses as sound.
  • The electrode array is inserted during an operation that usually takes between 2-3 hours depending on the device to be implanted. An incision is made behind the ear to expose the temporal bone; the temporal bone consists of the squamous, the mastoid, the tympanic, zygomatic and petrous segment. Typically, cochlear implants require the opening of the mastoid bone which leads to the middle ear. A shallow recess is then created to hold the implant package in place substantially level with the bone. Next a hole is drilled which allows the surgeon access into the cochlea. This hole is known as a cochleostomy—the opening from the middle ear to the perilymphatic canals of the cochlea. A cochleostomy may be formed through the round window 141, the oval window 110, the promontory or through the apical turn of the cochlea. The electrode array is then gently threaded into the shell-like structure of the cochlea and the incision closed; the cochleostomy remains open and heals with scar tissue over the next few days.
  • More recently various alternative approaches have been proposed to cause dynamic volume displacements of the perilymph, some of which require the implantation of an actuator that breaches the cochlea. These procedures require a cochleostomy or equivalent incision to provide the requisite access to the perilymphatic canals of the cochlea.
  • It is conventional during surgical implantation to use a tissue graft from the patient to provide a seal at the cochleostomy, primarily to reduce the risk of meningitis resulting from communication between the inner ear and the middle ear.
  • SUMMARY
  • In one aspect of the invention, an electrically nonconductive occludent id disclosed, the occludent constructed and arranged to forcefully infill a tissue opening so as to effectively prevent transport of electrical current, fluid and bacteria through the tissue opening.
  • In another aspect of the invention, a cochlear implant is disclosed, the cochlear implant comprising: an elongate electrode carrier member having at least one electrode disposed thereon, wherein the carrier member is configured to traverse a cochleostomy to position the electrodes in the cochlea; and an electrically nonconductive occludent constructed and arranged to circumferentially surround a portion of the carrier member traversing the cochleostomy, and to forcefully infill cochleostomy thereby segregating perilymphatic canals of the cochlea from extracochlear regions.
  • In a further embodiment of the present invention, a method for implanting an elongate carrier member in a cochlea of a recipient is disclosed, the method comprising: creating a cochleostomy; implanting the carrier member into the cochlea; and positioning an electrically nonconductive occludent in the cochleostomy so as to cause the portion of the carrier member and the occludent to forcefully infill the cochleostomy.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • An illustrative embodiment of the present invention will be described with reference to the accompanying figures, in which:
  • FIG. 1 is a perspective view of an example of an implanted cochlear implant suitable for implementing embodiments of the present invention;
  • FIG. 2A is a side view of an electrode assembly in accordance with one embodiment of the present invention;
  • FIG. 2B is a top view of the electrode assembly illustrated in FIG. 2A;
  • FIG. 3 is a schematic diagram of the cochlea showing a conventional intra-cochlear electrode insertion with the cochleostomy sealed using muscle/fat tissue;
  • FIG. 4 is a cross-sectional view of a portion of a cochlea showing an improved cochleostomy seal in accordance with one embodiment of the present invention;
  • FIG. 5 is a perspective view of one embodiment of the electrically nonconductive occludent of the present invention;
  • FIG. 6 is a perspective view of a human cochlea showing the embodiment of the occludent illustrated in FIG. 5 implanted in a cochleostomy, in accordance with embodiments of the present invention; and
  • FIG. 7 is a cross-sectional view of an alternative embodiment of a cochleostomy occludent of the present invention.
  • DETAILED DESCRIPTION
  • The present invention is generally directed to an electrically nonconductive occludent that forcefully infills and seals a cochleostomy or other tissue opening with or without an implantable component traversing the tissue opening. In one application described herein, an embodiment of the electrically nonconductive occludent is utilized to seal a cochleostomy having an implanted electrode assembly traversing therethrough, or other tissue opening such as the oval or round window with no such implanted component, thereby segregating the perilymphatic canals of the cochlea from extracochlear regions such as the middle ear. In certain embodiments, the occludent has a toroidal cross-sectional shape, circumferentially surrounding the implanted component such as an electrode carrier member.
  • The occludent may have a combination of one or more characteristics such as shape and durometer to partially enter the cochleostomy and to consume substantially all space between the carrier member and cochlea at the cochleostomy. The occludent may be permanently positioned on the carrier member, or it may be configured to slide over the carrier member to be positioned at the occluding position. In alternative embodiments, the occludent is configured to travel through the carrier member lumen to the occluding position. Such embodiments of the occludent may be configured to travel over the stylet used to implant the carrier member, or may be configured to be inserted with a tool for subsequent expansion. For example, the occludent may be a mechanical structure that is inflated mechanically or with a balloon.
  • Regardless of the method used to deploy the occludent, the region of the radially distensible carrier member containing the wedge dilates to consume the entire cochleostomy. Advantageously, the present invention provides a high electrical impedance blockage within the cochleostomy, thereby reducing the electric charge which may travel from the electrodes to, for example, an extracochlear reference electrode of the cochlear implant. It should be appreciated that the present invention is operable regardless of the relative size and location of the cochleostomy and carrier member regardless of whether the cochleostomy is formed through round window 141, the oval window 110, the promontory, the apical turn of the cochlea, or at any other therapeutically beneficial location to operatively reduce current flow through a tissue opening and thereby improve the electrical efficiency of the implant.
  • As noted, openings other than a cochleostomy may be made to accommodate the requirements of other types of prosthetic hearing implants. There are also circumstances that it is desirable to seal round window 141 and/or oval window 110 due to natural conditions, prior surgical procedure, etc. Such openings in tissue, whether they form naturally or occur due to disease, injury or surgery, are collectively and generally referred to herein as a tissue opening.
  • The present invention may be implemented in a variety of ways and the embodiments illustrated are to be considered only as illustrative constructions. More particularly, the present invention is potentially useful for purposes other than sealing a cochleostomy created as described herein. For example, the present invention may be applied to seal an existing orifice between the middle ear and the inner ear such as round window 141. The present invention may be used to seal any opening created between the middle ear and the perilymph, whether this is intended to be used as a conduit for a part of an implanted device, or to be sealed completely after surgery. The term cochleostomy should accordingly be understood for the purposes of this application in this expansive sense. Such sealing may have further advantages, for example reducing the chance of the recipient contracting meningitis. It may also reduce the risk of unintended explantation.
  • For the purpose of power reduction it is desirable to reduce the amount of electrical current required to stimulate the auditory nerve. During stimulation, as much as possible the current flowing from the electrode within the cochlea must be directed towards the auditory nerve. Any leakage of current through paths other through than the auditory nerve should therefore be minimised in order to reduce the power consumption of the implant. The present invention accordingly allows current leakage via the cochleostomy of a hearing implant prosthesis to be reduced. As a consequence, the current levels used for stimulation can be decreased as the implant's energy is used more efficiently.
  • Although many different stimulation approaches have been proposed and used, in each scheme the energy for the stimulations is provided by the implant, and conventionally this is supplied ultimately by the batteries in the external component. Hence, the degree to which the energy supplied by the batteries is effectively delivered impacts upon battery life.
  • Embodiments of the present invention are described below in connection with one type of stimulating medical device having an component implantable through a tissue opening; that is, a prosthetic hearing implant and, more specifically, a cochlear implant. Cochlear implants use direct electrical stimulation of auditory nerve cells to bypass absent or defective hair cells that normally transduce acoustic vibrations into neural activity. Such devices generally use multi-contact electrodes inserted into the scala tympani of the cochlea so that the electrodes may differentially activate auditory neurons that normally encode differential pitches of sound. Such devices are also used to treat a smaller number of patients with bilateral degeneration of the auditory nerve. For such patients, the cochlear implant provides stimulation of the cochlear nucleus in the brainstem. Such devices, therefore, are commonly referred to as auditory brainstem implants (ABIs).
  • Exemplary embodiments of a cochlear implant include a Contour™, Freedom™, Nucleus™ or Cochlear™ implant sold by Cochlear Limited, Australia. Such devices are described in U.S. Pat. Nos. 4,532,930, 6,537,200, 6,565,503, 6,575,894, and 6,697,674, the entire contents and disclosures of which are hereby incorporated by reference herein. It should be understood to those of ordinary skill in the art that embodiments of the present invention may be used in other stimulating medical devices such as neurostimulators, cardiac pacemakers/defibrillators, etc. as well as other medical devices which utilize an elongate carrier member to temporarily or permanently implant, deliver or otherwise introduce a therapeutic agent, sensor, device, etc. into a recipient.
  • FIG. 1 is a cut-away view of the relevant components of outer ear 101, middle ear 102 and inner ear 103, which are described next below. In a fully functional ear, outer ear 101 comprises an auricle 105 and an ear canal 106. An acoustic pressure or sound wave 107 is collected by auricle 105 and channeled into and through ear canal 106. Disposed across the distal end of ear cannel 106 is a tympanic membrane 104 which vibrates in response to acoustic wave 107. This vibration is coupled to oval window, or fenestra ovalis, 110 through three bones of middle ear 102, collectively referred to as the ossicles 111.
  • Ossicles 111 comprises the malleus 112, the incus 113 and the stapes 114. Bones 112, 113 and 114 of middle ear 102 serve to filter and amplify acoustic wave 107, causing oval window 110 to articulate, or vibrate. Such vibration sets up waves of fluid motion within cochlea 115. Such fluid motion, in turn, activates tiny hair cells (not shown) that line the inside of cochlea 115. Activation of the hair cells causes appropriate nerve impulses to be transferred through the spiral ganglion cells (not shown) to auditory nerve 116 and, ultimately, to the brain where they are perceived as sound. In some persons experiencing sensorineural hearing loss, there is an absence or destruction of the hair cells. Cochlear implant 120 is utilized to directly stimulate the ganglion cells to provide a hearing sensation to such persons.
  • FIG. 1 also shows how cochlear implant 120 is positioned in relation to outer ear 101, middle ear 102 and inner ear 103. Cochlear implant 120 comprises external component assembly 122 which is directly or indirectly attached to the body of the recipient, and an internal component assembly 124 which is temporarily or permanently implanted in the recipient. External assembly 122 comprises microphone 125 for detecting sound which is provided to a behind-the-ear (BTE) speech processing unit 126 that generates coded signals. The coded signals are provided to an external transmitter unit 128, along with power from a power source (not shown) such as a battery. External transmitter unit 128 comprises an external coil 130 and, preferably, a magnet (not shown) secured directly or indirectly in external coil 130.
  • Internal component assembly 124 comprises an internal receiver unit 132 having an internal coil (not shown) that transcutaneously receives power and coded signals from external assembly 122, and provides such signals to a stimulator unit 134. In response to the coded signals, stimulator 134 applies stimulation signals to cochlea 115 via an implanted electrode assembly 140. Electrode assembly 140 enters cochlea 115 via a cochleostomy 142, and has an array 144 of one or more electrodes 150 positioned to be substantially aligned with portions of tonotopically-mapped cochlea 115. The delivery of stimulation signals at various locations along cochlea 115 causes a hearing percept representative of the received sound 107.
  • While cochlear implant 120 is described as having external components, in another embodiment, the controller, including the microphone, speech processor and power supply, may also be implantable. In such embodiments, the controller may be contained within a hermetically sealed housing or the housing used for stimulator unit 134.
  • Electrode assembly 140 preferably assumes an optimal electrode position in cochlea 115 upon or immediately following implantation into the cochlea. It is also desirable that electrode assembly 140 be configured such that the insertion process causes minimal trauma to the sensitive structures of cochlea 115. Usually electrode assembly 140 is pre-curved, held in a straight configuration at least during the initial stages of the implantation procedure, conforming to the natural shape of the cochlea during and subsequent to implantation.
  • FIG. 2A is a side view of an embodiment of electrode assembly 140, referred to herein as electrode assembly 200. FIG. 2B is a top view of electrode assembly 200. Electrode assembly 200 comprises a carrier member 202, a stop member 204 and lead 206. Carrier member 202 has a distal end 208 adapted to be implanted furthest into cochlea 115, and a proximal end 210 connected to a distal end 214 of laterally-extending stop member 204. The opposing proximal end 216 of stop member 204 is connected to lead 206. Lead 206 physically and electrically connects electrode assembly 200 with stimulator unit 134.
  • When implanted in a recipient, the surface of carrier member 202 which faces the interior of cochlea 115 is referred to herein as the medial surface 216 of carrier member 202. The opposing side of carrier member 202, referred to herein as lateral surface 218, faces the external wall and bony capsule (not shown) of cochlea 115. It should be understood that the terms medial surface, medial direction, and the like, are generally used herein to refer to the surfaces, features and directions toward the center of cochlea 115, while the terms lateral surface, lateral direction, and the like, are generally used herein to refer to surfaces, features and directions toward the exterior of cochlea 115. In addition, a longitudinal axis 250 is utilized herein to facilitate descriptions herein.
  • A plurality of spaced-apart electrodes 212 are mounted on or in carrier member 202. Electrodes 212 may be disposed in a linear or non-linear array on or in carrier member 202, and may be positioned to align with predetermined regions of tonotopically mapped cochlea 115. In alternative embodiments, electrodes 212 are implemented as described in U.S. Provisional Patent Application No. 60/748,217, 60/748,273 and 60/748,314, hereby incorporated by reference herein.
  • FIG. 3 is a schematic of cochlear 115 showing a conventional, intra-cochlear electrode insertion, where cochleostomy 142 is sealed using a graft 302 of the recipient's tissue, typically muscle and fat. In this illustrative example, cochleostomy 142 is shown in an exterior wall 304 of cochlea 115, and is situated in the space of middle ear 102. Graft 302 is positioned around carrier member 140 over cochleostomy 142, as shown in FIG. 3.
  • FIG. 4 is a cross-sectional view of a portion of a cochlea showing an improved cochleostomy seal in accordance with one embodiment of the present invention. In this exemplary embodiment, a deformable electrically nonconductive occludent 400 is inserted into cochleostomy 142 to prevent the transfer of fluids, bacteria and electrical current through cochleostomy 142. In one particular embodiment, occludent 400 is formed from a soft, deformable grade of silicone elastomer. Such combination of characteristics allows occludent 400 to elastically conform to the generally irregular shape of cochleostomy 142.
  • Occludent 400 may be formed around elongate electrode carrier member 140 so that it can slide along the carrier member. For example, in one embodiment, occludent 400 has an aperture suitable for slidingly receiving the implantable component that is to be traversing through the tissue opening, here carrier member 140 traversing cochleostomy 142. In practice, the surgeon would insert electrode carrier member 140 through cochleostomy 142 and into cochlea 115 in a conventional manner. This process is well understood in the art, and described in the literature, and conventional aspects of this process will not be further described in detail. A standard reference for such a process is described in “Surgical Techniques for Cochlear Implants”, Noel L. Cohen, Chapter 8, p 151 in “Cochlear Implants”, Waltzman, S. B. and Cohen, L. L. (1997) ISBN 0-86577-882-5, the disclosure of which is hereby incorporated by reference.
  • The extent of insertion will vary significantly from recipient to recipient, depending upon the peculiarities of the anatomy of the recipient, the specific surgical procedure used by the surgeon, and the precise location of cochleostomy 142. It is expected that the most improvement in leakage reduction will be for the basal electrodes 150, as these electrodes have the shortest leakage path. It therefore also follows that greater improvement may be seen in short or partial electrode arrays, for example as used in electro-acoustic stimulation.
  • After carrier member 140 has been inserted as far as desired, occludent 400 may be slid along electrode carrier member 140 to be partially inside cochlea 115 and partially outside cochlea 115; that ins occludent 400 infills cochleostomy 142. Because this embodiment of occludent 400 has an exterior radius that is larger than the interior radius of cochleostomy 142, and because occludent 400 is malleable; that is, has a low durometer, it deforms to partially enter cochlea 115 thereby forcefully infilling cochleostomy 142 so as to effectively prevent transport of electrical current, fluid and bacteria through the cochleostomy. In other words, occludent 400 fills the available space between the walls of cochlea 115 defining cochleostomy 142 and the exterior of carrier member 140 which passes through the cochleostomy. Furthermore, occludent 400 sufficiently infills cochleostomy 142 so that fluids, bacteria, etc., cannot pass through an remaining apertures between cochlea 115 and occludent 400. Thus, occludent 400 provides a seal of electrically nonconductive, or insulating, biocompatible material within cochleostomy 142. Occludent 400 thereby increases the impedance of the undesired current path through cochleostomy 142 to the reference electrode (not shown) of cochlear implant 120 located outside the inner ear 103. It should be appreciated to those of ordinary skill in the art that as the anatomical structures surrounding occludent 400 are partially conductive and, as such, electric current may still leak through this general region, but current leakage through cochleostomy 142 will be reduced.
  • The embodiment of occludent 400 shown in FIG. 4 is generally toroidal in shape, as it surrounds electrode carrier member 140 and infills cochleostomy 142 as described above. However, any other suitable shape may be used. One such suitable shape is a truncated cone 500, as shown in FIGS. 5 and 6. FIG. 5 is a perspective view of an occludent 500 having a truncated cone configuration, while FIG. 6 is a perspective view of occludent 500 inserted into cochleostomy 142 of cochlea 115.
  • The end 504 of truncated cone occludent 500 which is has a smaller diameter is dimensioned to easily pass through cochleostomy 142 to enable occludent 500 to enter cochlea 115. Conversely, the end 508 of occludent 500 which is has a relatively greater diameter is dimensioned to no pass through cochleostomy 142. As such, occludent 500 forcefully infills cochleostomy 142 as it is inserted into the cochleostomy, thereby sealing cochlea 115. In one embodiment, body 506 of occludent 500 is also malleable to enable the occludent to deform in response to the forced insertion of the occludent, further insuring a forceful infilling sufficient to seal cochleostomy 142. As shown in FIG. 6, when implanted, base 508 of occludent 500 remains on the outside of cochleostomy 142, allowing for easy removal should that be necessary.
  • As noted above with reference to the embodiment of the electrically nonconducting occludent 400, occludent 500 may be implemented as an integrated or unitary element of electrode carrier member 140, or it may be a separately manufactured component that has a channel 502 dimmensioned to slide over carrier member 140. In either embodiment, once electrode carrier member 140 is in a suitable position and occludent 500 is in the occluding position; that is, partially infilling cochleostomy 142, occludent 400 seals cochleostomy 142.
  • Occludent 500 may be formed of any suitable inert biocompatible material that is operatively an electrical insulator. In one embodiment, occludent 500 is preferably formed of silicone. It should be appreciated, however, that occludent 500 may be formed of different materials or from a combination of one or more other material. It could be partly formed from a more stiff material, with the outer portions being resilient in order to provide the necessary conformable seal.
  • Occludent 500 may be formed from a suitable polymer putty material in situ. It could be formed, with a slit or the like, to allow it to be attached around the electrode carrier member 140 after insertion. Importantly, occludent 500 is formed of an insulating material and substantially seal cochleostomy 142 so as increase the impedance of the leakage path. If different shapes or forms of electrode carrier member 140 are used, then the shape of the occludent 500 will need to be adapted to suit the shape of the implanted carrier member which traverses cochleostomy 142.
  • Alternatively, as shown in FIG. 7, an alternative embodiment of the present invention, carrier member 140 is radially distensible and has a longitudinally-extending lumen 706. In one embodiment, lumen 706 is configured to receive a stylet as is conventionally utilized in certain pre-curved electrode carrier members. In an alternative embodiment, lumen 706 is configured to interoperate with occludent 700 as described herein.
  • Occludent 700 is configured to be slidingly passed through lumen 706 as shown in FIG. 7. The exterior dimensions of occludent 700 are larger than the interior dimensions of lumen 706. As such, occludent 700 applied a force radially outward in that region of carrier member 702 in which occludent 700 is located. Because carrier member 702 is outwardly distensible, such force causes carrier member 702 to dilate or expand in the region containing occludent 700, as shown in FIG. 7. In such embodiments, advancing occludent 700 to be partially inside cochlea 115; that is, to infill cochleostomy 142, causes carrier member 702 to expand to abut the perimeter of cochlea 115 that defines cochleostomy 142.
  • Occludent 700 may take on any form necessary. In the embodiment shown in FIG. 7, occludent 700 is solid. Alternatively occludent 700 may be hollow. In the embodiment shown in FIG. 7, occludent 700 is distally tapered and has round edges. This is ti avoid damage to in interior surfaces of carrier member 702 defining lumen 706. it should be appreciated, however, that occludent 700 may take on other shapes in alternative embodiments.
  • In operation, occludent 700 is initially located near a proximal end of electrode carrier member 702 so that it does not interfere with the normal insertion of the carrier member. After insertion of electrode carrier member 702, occludent 700 is slid along lumen 706 to cochleostomy 142 where it deforms the sides of carrier member 702 sufficiently to seal the cochleostomy 142. This embodiment has the further advantage in that two separate components do not abut to create a potential space, thereby reducing the risk of infection.
  • It should be appreciated that tools or guide wires may be used to facilitate the advancement of occludent 700 in lumen 706. For example, in the example shown in FIG. 7, a guide wire 704 is provided, and occludent 700 has an aperture for sliding receiving the guide wire 704. Alternatively, occludent 700 may be detachably secured to the distal end of a tool that may be advance into lumen 706.
  • Alternatively, occludent 700 may be formed by being moulded as part of the electrode moulding process, at an appropriate location along the length of electrode carrier member 702. In such embodiments, implantation of electrode carrier member 702 is performed until occludent 700 is positioned in cochleostomy 142.
  • Such an embodiment has the same advantage as the sliding space filling plug of FIG. 7 in that it has no separate insulator parts abutting and therefore has a reduced risk of infection. It also has the advantage of not requiring a small device to be moved, relative to the array, in the confined space and delicate structures of the inner ear during implantation.
  • In alternative embodiment, occludent 700 may be initially of smaller dimensions whan advanced through lumen 706, and then expanded to a larger size to effect the radial distension of carrier member 702 noted above. Such an expansion may be achieved in many ways now or later developed, such as by implementing mechanically expandable members, a material that expands in response to the pumping of air or other fluid, the mixing of materials, and the like.
  • It should also be appreciated that the occludent of the present invention may be specifically shaped to fit an actual aperture, for example the oval window. Alternatively, it could be formed in situ, for example by a fast curing sealant injected around the cochleostomy 142. Any effective artificial seal which can be positioned as required may be used to implement the invention.
  • The efficacy of implementing embodiments of the present invention has been investigated using an animal model. Experiments on two Guinea Pigs, with a total of three ears investigated acutely have been performed. In these experiments, the bulla (middle ear cavity) was exposed, a cochleostomy was drilled over the round window and a four electrode array was inserted. Stimulation was applied between the most apical intracochlear electrode (ICE) and a monopolar ball electrode inserted in the temporalis muscle.
  • Monopolar Electrical Auditory Brainstem Response (EABR) thresholds and the voltage waveform between the stimulus electrodes (to deduce impedance) were measured. In the last of the three ears investigated the voltage between the two most basal ring electrodes was also measured during the stimulus pulse (to determine the current flow along the cochlea at a point near the cochleostomy).
  • To calibrate this measurement a known current pulse had been previously applied between the most apical ICE and another ring electrode (on a separate array) held by hand in the cochleostomy.
  • Four different methods of sealing the cochleostomy were used: no sealing; small piece of muscle of approx. the volume of the cochleostomy; larger piece of muscle several times the volume of the cochleostomy (residual muscle extending out of the cochleostomy) and otoform paste (one ear only).
  • Otoform paste is a settable silicone material, used in hearing aid fitting and similar applications, which is initially mouldable but which then sets to a soft deformable consistency.
  • In every ear the EABR thresholds, the impedance and the current flow at the cochleostomy varied depending on the plug type used. The following table shows the four sealing methods and how those parameters varied:
  • Plug material EABR T Impedence (Z) Cochleostomy current
    Large muscle Largest lowest Largest
    Small muscle 2nd largest 2nd lowest 2nd largest
    No seal 3rd largest 3rd lowest 3rd largest
    Otoform putty Smallest highest smallest
  • The smallest EABR threshold (otoform putty) was about 40% smaller than the largest threshold (large muscle). The impedance results varied by around 20-35% from smallest to largest. The current flow through the cochleostomy varied from 84% of total current (large muscle) to 70% (otoform putty).
  • The results are consistent with a significant proportion of the stimulus current flowing through the cochleostomy. Different sealing arrangements appear to change the amount of current flow through the cochleostomy and thereby change the EABR threshold. The changes in impedance and cochleostomy current flow as measured by the voltage on the basal two rings are consistent with this model. These results indicate it is possible to lower thresholds by effective sealing of the cochleostomy.
  • Another perspective is that any T and C decrease gained from using the plug will manifest itself as a decrease in power consumption of the implant and a subsequent increase in battery life. Power consumption of the implant can be divided into two parts—power consumed to run the implant electronics (WE) and power consumed to deliver current to the auditory nerve (WN). The decrease in T/C level current will manifest itself as a proportional decrease in WN. For present implant designs the ratio of WN to WE is about 50:50 for high rate strategies. If, for example, it is assumed that the plug provides a 10% decrease in T/C level this would translate to about a 5% decrease in overall implant power consumption for high rate strategies, less for lower rate strategies. However, the most recent tests show that the plug yields an improvement of between 20-40% decrease in T/C level, indicating at lease a 10% improvement in power consumption.
  • Variations and additions are possible to the structures described within the general scope of the present invention. For example, embodiments of the present invention may be employed in addition to a tissue graft type sealing approach.
  • Although the present invention has been principally described with reference to a cochlear implant prosthesis, it will be appreciated that embodiments of the present invention may readily be applied to provide a nonconductive seal of a tissue opening regardless of whether a carrier member 140 or other implant prosthesis or component is positioned within the tissue opening. Such applications in which there are electrical losses through the tissue opening may particularly benefit from the present invention. It should also be understood that although the description has referred principally to a prosthetic hearing implant with an external receiver/stimulator unit 134, embodiments of the present invention are equally applicable to a totally implanted device.
  • It will also be appreciated that although this invention has been principally used to provide sealing at the cochleostomy there are other tissue openings between cochlea 115 and middle ear 102 that may pass similar electric current and that may also provide similar benefit by being sealed with an embodiment of the electrically nonconductive occludent of the present invention. These include round window 141 and oval window 110. Embodiments of the electrically nonconductive occludent of the present invention which are not integrated in or unitary with a carrier member may be inserted into these other tissue openings, providing a further decrease in stray electrical current. It will be understood that the present invention may also be applied to seal a cochleostomy which is not intended to remain open, for example in some form of totally implanted device which does not require a physical conduit to remain out of inner ear 103.
  • All documents, patents, journal articles and other materials cited in the present application are hereby incorporated by reference.
  • Although the present invention has been fully described in conjunction with several embodiments thereof with reference to the accompanying drawings, it is to be understood that various changes and modifications may be apparent to those skilled in the art. Such changes and modifications are to be understood as included within the scope of the present invention as defined by the appended claims, unless they depart therefrom.

Claims (46)

1. An electrically nonconductive occludent constructed and arranged to forcefully infill a tissue opening so as to effectively prevent transport of electrical current, fluid and bacteria through the tissue opening.
2. The occludent of claim 1, wherein a component traverses the tissue opening, and further wherein said occludent is configured to circumferentially surround a portion of the component traversing the tissue opening.
3. The occludent of claim 2, wherein the component is an electrode carrier member, and further wherein said occludent is configured to circumferentially surround said electrode carrier member thereby segregating perilymphatic canals of the cochlea from extracochlear regions.
4. The occludent of claim 3, wherein the electrode carrier member is a component of a prosthetic hearing implant.
5. The occludent of claim 3, wherein the prosthetic hearing implant comprises a cochlear implant.
6. The occludent of claim 4, wherein the tissue opening is a cochleostomy.
7. The occludent of claim 5, wherein the cochleostomy is formed through one of either the cochlea round window, the cochlea oval window, the cochlea promontory, and the cochlea apical turn.
8. The occludent of claim 2, wherein the tissue opening is an opening in a cochlea.
9. The occludent of claim 1, wherein a component traverses the tissue opening, and further wherein said occludent has an aperture formed therein to receive a portion of the component traversing the tissue opening.
10. The occludent of claim 10, wherein said occludent has a toroidal cross-sectional shape.
11. The occludent of claim 10, wherein said occludent has a combination of one or more characteristics to enable said occludent to forcefully consume substantially all space between the carrier member and cochlea at the cochleostomy.
12. The occludent of claim 10, wherein said occludent is permanently positioned on the electrode carrier member.
13. The occludent of claim 2, wherein said occludent is further configured to slidingly receive the component.
14. The occludent of claim 11, wherein said characteristics comprise one or more of the group consisting of shape and durometer.
15. The occludent of claim 2, wherein said component is radially distensible and has a accessible orifice disposed therein, and further wherein said occludent is configured to be slidingly adjusted within the orifice.
16. The occludent of claim 15, wherein said occludent has a surface configuration that tapers distally.
17. The occludent of claim 15, wherein said orifice is a lumen longitudinally disposed in the electrode carrier member.
18. The occludent of claim 17, wherein the lumen is configured to receive a stylet, and further wherein said occludent is configured to travel over the stylet.
19. The occludent of claim 15, wherein said occludent is expandable, such that when expanded while located in the lumen, said occludent causes the carrier member to radially dilate to seal the cochleostomy.
20. The occludent of claim 1, wherein said occludent is formed from a resilient, deformable material so that operatively it conforms substantially to the surface of the tissue opening.
21. The occludent of claim 20, wherein said resilient, deformable material comprises silicone.
22. The occludent of claim 20, wherein said resilient, deformable material comprises silicone.
23. The occludent of claim 3, wherein said occludent is a truncated cone.
24. A cochlear implant comprising:
an elongate electrode carrier member having at least one electrode disposed thereon, wherein the carrier member is configured to traverse a cochleostomy to position the electrodes in the cochlea; and
an electrically nonconductive occludent constructed and arranged to circumferentially surround a portion of the carrier member traversing the cochleostomy, and to forcefully infill cochleostomy thereby segregating perilymphatic canals of the cochlea from extracochlear regions.
25. The cochlear implant of claim 24, wherein the cochleostomy is formed through one of either the cochlea round window, the cochlea oval window, the cochlea promontory, and the cochlea apical turn.
26. The cochlear implant of claim 24, wherein said occludent has an aperture formed therein to receive a portion of the carrier member.
27. The cochlear implant of claim 24, wherein said occludent has a toroidal cross-sectional shape.
28. The cochlear implant of claim 24, wherein said occludent has a combination of one or more characteristics including shape and durometer to enable said occludent to forcefully consume substantially all space between the carrier member and cochlea at the cochleostomy.
29. The cochlear implant of claim 24, wherein said occludent and said electrode carrier member are fixedly integrated.
30. The cochlear implant of claim 24, wherein said occludent and said electrode carrier member are unitary.
31. The cochlear implant of claim 24, wherein said occludent is further configured to slidingly receive the component.
32. The cochlear implant of claim 27, wherein said occludent is further configured to slidingly receive the component.
33. The cochlear implant of claim 24, wherein said carrier member is radially distensible and has a lumen longitudinally disposed in the electrode carrier member, and further wherein said occludent is configured to be slidingly adjusted within the lumen.
34. The cochlear implant of claim 33, wherein said occludent has a surface configuration that tapers distally.
35. The cochlear implant of claim 33, wherein the lumen is configured to receive a stylet, and further wherein said occludent is configured to travel over the stylet
36. The cochlear implant of claim 33, wherein said occludent is expandable, such that when expanded while located in the lumen, said occludent causes the carrier member to radially dilate to seal the cochleostomy.
37. The cochlear implant of claim 24, wherein said occludent is formed from a resilient, deformable material so that operatively it conforms substantially to the surface of the tissue opening.
38. The occludent of claim 37, wherein said resilient, deformable material comprises silicone.
39. The occludent of claim 37, wherein said resilient, deformable material comprises silicone.
40. The occludent of claim 24, wherein said occludent is a truncated cone.
41. A method for implanting an elongate carrier member in a cochlea of a recipient, comprising:
creating a cochleostomy;
implanting the carrier member into the cochlea; and
positioning an electrically nonconductive occludent in the cochleostomy so as to cause the portion of the carrier member and the occludent to forcefully infill the cochleostomy.
42. The method of claim 41, wherein said occludent is configured to circumferentially surround a portion of the carrier member traversing the cochleostomy.
43. The method of claim 41, wherein creating the cochleostomy comprising:
forming the cochleostomy through one of either the cochlea round window, the cochlea oval window, the cochlea promontory, and the cochlea apical turn.
44. The method of claim 41, wherein said occludent has an aperture formed therein to receive a portion of said carrier member traversing the cochleostomy, and wherein positioning the occludent in the cochleostomy comprises:
sliding said occludent over said carrier member until at least a portion of said occludent infills said cochleostomy.
45. The method of claim 41, wherein said occludent is permanently positioned on the electrode carrier member, and wherein positioning the occludent in the cochleostomy comprises:
implanting said carrier member to a depth at which at least a portion of said occludent infills said cochleostomy.
46. The method of claim 41, wherein said carrier member is radially distensible and has a accessible lumen longitudinally disposed therein, wherein said occludent is configured to be slidingly adjusted within the orifice, and further wherein positioning the occludent in the cochleostomy comprises:
sliding said occludent through said lumen into at least a portion of said occludent infill said cochleostomy, wherein said occludent causes the carrier member to radially dilate to seal the cochleostomy.
US11/614,851 2005-12-21 2006-12-21 Electrically Nonconductive Occludent For Tissue Openings Abandoned US20080154339A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/614,851 US20080154339A1 (en) 2006-12-21 2006-12-21 Electrically Nonconductive Occludent For Tissue Openings
US13/303,631 US9345876B2 (en) 2005-12-21 2011-11-23 Cochlear implant having electrically nonconductive occludent for tissue openings

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/614,851 US20080154339A1 (en) 2006-12-21 2006-12-21 Electrically Nonconductive Occludent For Tissue Openings

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/303,631 Continuation US9345876B2 (en) 2005-12-21 2011-11-23 Cochlear implant having electrically nonconductive occludent for tissue openings

Publications (1)

Publication Number Publication Date
US20080154339A1 true US20080154339A1 (en) 2008-06-26

Family

ID=39544023

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/614,851 Abandoned US20080154339A1 (en) 2005-12-21 2006-12-21 Electrically Nonconductive Occludent For Tissue Openings
US13/303,631 Expired - Fee Related US9345876B2 (en) 2005-12-21 2011-11-23 Cochlear implant having electrically nonconductive occludent for tissue openings

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/303,631 Expired - Fee Related US9345876B2 (en) 2005-12-21 2011-11-23 Cochlear implant having electrically nonconductive occludent for tissue openings

Country Status (1)

Country Link
US (2) US20080154339A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070179566A1 (en) * 2002-06-28 2007-08-02 Cochlear Limited Cochlear implant electrode array
US20080234793A1 (en) * 2007-03-20 2008-09-25 Cochlear Limited Securing an implanted medical device in a patient
US20090254163A1 (en) * 2007-03-20 2009-10-08 Cochlear Limited Securing an implanted medical device in a patient
US20100094311A1 (en) * 2008-10-15 2010-04-15 Med-El Elektromedizinische Geraete Gmbh Implant Electrode and Accessories for Use in Robotic Surgery
US20100114288A1 (en) * 2008-10-31 2010-05-06 Advanced Bionics, Llc Cochlear electrode insertion
US20110093049A1 (en) * 2009-10-16 2011-04-21 Uwe Hinrichsen Apparatus for stimulating auricular points on the human ear
WO2011053766A1 (en) * 2009-10-30 2011-05-05 Advanced Bionics, Llc Steerable stylet
CN102573988A (en) * 2009-08-03 2012-07-11 耳蜗有限公司 Implant stimulation device
US9143396B2 (en) 2011-03-25 2015-09-22 Huawei Technologies Co., Ltd. VPLS fast rerouting method and device
US9345876B2 (en) 2005-12-21 2016-05-24 Cochlear Limited Cochlear implant having electrically nonconductive occludent for tissue openings
US9375565B2 (en) 2013-10-28 2016-06-28 Cochlear Limited Stimulating assembly fixation features
EP3104930A4 (en) * 2014-02-11 2017-07-12 MED-EL Elektromedizinische Geraete GmbH Electrode with anti-spring back component
WO2018078509A1 (en) * 2016-10-28 2018-05-03 Cochlear Limited Barriers for electrodes
WO2022172135A1 (en) * 2021-02-09 2022-08-18 Cochlear Limited Integrated tube sheath
WO2023031711A1 (en) * 2021-09-01 2023-03-09 Cochlear Limited Cured ring seal
US11612745B2 (en) * 2018-04-24 2023-03-28 Cochlear Limited Inner ear electrode implantation outcome assessment

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014201511A1 (en) * 2013-06-21 2014-12-24 Gary David Housley Method and apparatus for close-field electroporation
WO2016009371A1 (en) 2014-07-17 2016-01-21 Cochlear Limited Implantable stimulating assembly arrangements
US11006229B2 (en) 2017-02-27 2021-05-11 Med-El Elektromedizinische Geraete Gmbh Middle ear implant coupler for mechanical cochlea stimulation via the round window
US11071856B2 (en) 2017-03-24 2021-07-27 Cochlear Limited Advanced electrode array location evaluation

Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487210A (en) * 1982-11-15 1984-12-11 Minnesota Mining And Manufacturing Company Anchor for anchoring electrode leads used in cochlear implantation
US4532930A (en) * 1983-04-11 1985-08-06 Commonwealth Of Australia, Dept. Of Science & Technology Cochlear implant system for an auditory prosthesis
US4608057A (en) * 1985-06-03 1986-08-26 Texaco Inc. Clear stable motor fuel composition
US4645504A (en) * 1985-05-24 1987-02-24 The Regents Of The University Of California Implantable infection barrier seal and method
US4795426A (en) * 1987-04-02 1989-01-03 Solutech, Inc. Catheter introducing device and method of placing catheter
US4892108A (en) * 1987-07-23 1990-01-09 The Regents Of The University Of Michigan Multi-channel extracochlear implant
US4898183A (en) * 1987-07-24 1990-02-06 Cochlear Pty. Limited Apparatus and method for insertion of cochlear electrode assembly
US5267968A (en) * 1992-07-09 1993-12-07 Russo Ronald D Retention bolster for percutaneous catheters
US20020156513A1 (en) * 2000-08-17 2002-10-24 Borkan William N. Spinal cord stimulation leads
US6537200B2 (en) * 2000-03-28 2003-03-25 Cochlear Limited Partially or fully implantable hearing system
US6565503B2 (en) * 2000-04-13 2003-05-20 Cochlear Limited At least partially implantable system for rehabilitation of hearing disorder
US6575894B2 (en) * 2000-04-13 2003-06-10 Cochlear Limited At least partially implantable system for rehabilitation of a hearing disorder
US6628991B2 (en) * 2000-04-28 2003-09-30 Advanced Bionics Corporation Minimally-invasive access into the cochlea for electrode insertion and fluid delivery
US6697674B2 (en) * 2000-04-13 2004-02-24 Cochlear Limited At least partially implantable system for rehabilitation of a hearing disorder
US20040225336A1 (en) * 2003-02-21 2004-11-11 Dusan Milojevic Telescopic array for a cochlear implant
US6889094B1 (en) * 1999-05-14 2005-05-03 Advanced Bionics Corporation Electrode array for hybrid cochlear stimulator
US20050139016A1 (en) * 2001-06-11 2005-06-30 Yamato Scale Co., Ltd. Load sensor with use of crystal resonator
US20050256561A1 (en) * 2002-06-28 2005-11-17 Gantz Bruce J Cochlear implant electrode array
US7146227B2 (en) * 2000-10-04 2006-12-05 Cochlear Limited Combination stylet and straightening coating for a cochlear implant electrode array
US7194314B1 (en) * 2003-08-15 2007-03-20 Northwestern University Cochlear implant including a modiolar return electrode
US20070135884A1 (en) * 2005-12-08 2007-06-14 Cochlear Limited Promoting curvature and maintaining orientation of an electrode carrier member of a stimulating medical device
US20070162098A1 (en) * 2005-12-08 2007-07-12 Cochlear Limited Prosthetic hearing implant electrode assembly having optimal length for atraumatic implantation
US20080234793A1 (en) * 2007-03-20 2008-09-25 Cochlear Limited Securing an implanted medical device in a patient
US20090254163A1 (en) * 2007-03-20 2009-10-08 Cochlear Limited Securing an implanted medical device in a patient

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006252212A1 (en) 2005-12-21 2007-07-05 Cochlear Limited Improved cochleostomy sealing
US20080154339A1 (en) 2006-12-21 2008-06-26 Cochlear Limited Electrically Nonconductive Occludent For Tissue Openings

Patent Citations (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487210A (en) * 1982-11-15 1984-12-11 Minnesota Mining And Manufacturing Company Anchor for anchoring electrode leads used in cochlear implantation
US4532930A (en) * 1983-04-11 1985-08-06 Commonwealth Of Australia, Dept. Of Science & Technology Cochlear implant system for an auditory prosthesis
US4645504A (en) * 1985-05-24 1987-02-24 The Regents Of The University Of California Implantable infection barrier seal and method
US4608057A (en) * 1985-06-03 1986-08-26 Texaco Inc. Clear stable motor fuel composition
US4795426A (en) * 1987-04-02 1989-01-03 Solutech, Inc. Catheter introducing device and method of placing catheter
US4892108A (en) * 1987-07-23 1990-01-09 The Regents Of The University Of Michigan Multi-channel extracochlear implant
US4898183A (en) * 1987-07-24 1990-02-06 Cochlear Pty. Limited Apparatus and method for insertion of cochlear electrode assembly
US5267968A (en) * 1992-07-09 1993-12-07 Russo Ronald D Retention bolster for percutaneous catheters
US6889094B1 (en) * 1999-05-14 2005-05-03 Advanced Bionics Corporation Electrode array for hybrid cochlear stimulator
US6537200B2 (en) * 2000-03-28 2003-03-25 Cochlear Limited Partially or fully implantable hearing system
US6565503B2 (en) * 2000-04-13 2003-05-20 Cochlear Limited At least partially implantable system for rehabilitation of hearing disorder
US6575894B2 (en) * 2000-04-13 2003-06-10 Cochlear Limited At least partially implantable system for rehabilitation of a hearing disorder
US6697674B2 (en) * 2000-04-13 2004-02-24 Cochlear Limited At least partially implantable system for rehabilitation of a hearing disorder
US6628991B2 (en) * 2000-04-28 2003-09-30 Advanced Bionics Corporation Minimally-invasive access into the cochlea for electrode insertion and fluid delivery
US20020156513A1 (en) * 2000-08-17 2002-10-24 Borkan William N. Spinal cord stimulation leads
US7146227B2 (en) * 2000-10-04 2006-12-05 Cochlear Limited Combination stylet and straightening coating for a cochlear implant electrode array
US20050139016A1 (en) * 2001-06-11 2005-06-30 Yamato Scale Co., Ltd. Load sensor with use of crystal resonator
US20050256561A1 (en) * 2002-06-28 2005-11-17 Gantz Bruce J Cochlear implant electrode array
US20040225336A1 (en) * 2003-02-21 2004-11-11 Dusan Milojevic Telescopic array for a cochlear implant
US7194314B1 (en) * 2003-08-15 2007-03-20 Northwestern University Cochlear implant including a modiolar return electrode
US20070135884A1 (en) * 2005-12-08 2007-06-14 Cochlear Limited Promoting curvature and maintaining orientation of an electrode carrier member of a stimulating medical device
US20070162098A1 (en) * 2005-12-08 2007-07-12 Cochlear Limited Prosthetic hearing implant electrode assembly having optimal length for atraumatic implantation
US20080234793A1 (en) * 2007-03-20 2008-09-25 Cochlear Limited Securing an implanted medical device in a patient
US20090254163A1 (en) * 2007-03-20 2009-10-08 Cochlear Limited Securing an implanted medical device in a patient

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070179566A1 (en) * 2002-06-28 2007-08-02 Cochlear Limited Cochlear implant electrode array
US9119957B2 (en) 2002-06-28 2015-09-01 Cochlear Limited Cochlear implant system component having multiple electrode assemblies
US9345876B2 (en) 2005-12-21 2016-05-24 Cochlear Limited Cochlear implant having electrically nonconductive occludent for tissue openings
US8718795B2 (en) * 2007-03-20 2014-05-06 Cochlear Limited Securing an implanted medical device in a patient
US20080234793A1 (en) * 2007-03-20 2008-09-25 Cochlear Limited Securing an implanted medical device in a patient
US20090254163A1 (en) * 2007-03-20 2009-10-08 Cochlear Limited Securing an implanted medical device in a patient
US20180104474A1 (en) * 2007-03-20 2018-04-19 Peter Gibson Securing an implanted medical device in a patient
US11426576B2 (en) 2007-03-20 2022-08-30 Cochlear Limited Securing an implanted medical device in a patient
US10661076B2 (en) * 2007-03-20 2020-05-26 Cochlear Limited Securing an implanted medical device in a patient
US9402990B2 (en) * 2007-03-20 2016-08-02 Cochlear Limited Securing an implanted medical device in a patient
US20220355101A1 (en) * 2007-03-20 2022-11-10 Peter Gibson Securing an implanted medical device in a patient
WO2010053673A2 (en) * 2008-10-15 2010-05-14 Med-El Elektromedizinische Geraete Gmbh Implant electrode and accessories for use in robotic surgery
CN102186533A (en) * 2008-10-15 2011-09-14 Med-El电气医疗器械有限公司 Implant electrode and accessories for use in robotic surgery
WO2010053673A3 (en) * 2008-10-15 2010-07-22 Med-El Elektromedizinische Geraete Gmbh Implant electrode and accessories for use in robotic surgery
US20100094311A1 (en) * 2008-10-15 2010-04-15 Med-El Elektromedizinische Geraete Gmbh Implant Electrode and Accessories for Use in Robotic Surgery
US8594799B2 (en) 2008-10-31 2013-11-26 Advanced Bionics Cochlear electrode insertion
US20100114288A1 (en) * 2008-10-31 2010-05-06 Advanced Bionics, Llc Cochlear electrode insertion
CN102573988A (en) * 2009-08-03 2012-07-11 耳蜗有限公司 Implant stimulation device
US8761872B2 (en) * 2009-10-16 2014-06-24 16Max Corporation Apparatus for stimulating auricular points on the human ear
US20110093049A1 (en) * 2009-10-16 2011-04-21 Uwe Hinrichsen Apparatus for stimulating auricular points on the human ear
US20110106101A1 (en) * 2009-10-30 2011-05-05 Advanced Bionics, Llc Steerable Stylet
US9211403B2 (en) 2009-10-30 2015-12-15 Advanced Bionics, Llc Steerable stylet
WO2011053766A1 (en) * 2009-10-30 2011-05-05 Advanced Bionics, Llc Steerable stylet
US9143396B2 (en) 2011-03-25 2015-09-22 Huawei Technologies Co., Ltd. VPLS fast rerouting method and device
US9375565B2 (en) 2013-10-28 2016-06-28 Cochlear Limited Stimulating assembly fixation features
EP3104930A4 (en) * 2014-02-11 2017-07-12 MED-EL Elektromedizinische Geraete GmbH Electrode with anti-spring back component
CN109891915A (en) * 2016-10-28 2019-06-14 科利耳有限公司 For the barrier of electrode
WO2018078509A1 (en) * 2016-10-28 2018-05-03 Cochlear Limited Barriers for electrodes
EP3533241A4 (en) * 2016-10-28 2020-05-27 Cochlear Limited Barriers for electrodes
US11738193B2 (en) 2016-10-28 2023-08-29 Cochlear Limited Barriers for electrodes
US11612745B2 (en) * 2018-04-24 2023-03-28 Cochlear Limited Inner ear electrode implantation outcome assessment
WO2022172135A1 (en) * 2021-02-09 2022-08-18 Cochlear Limited Integrated tube sheath
WO2023031711A1 (en) * 2021-09-01 2023-03-09 Cochlear Limited Cured ring seal

Also Published As

Publication number Publication date
US9345876B2 (en) 2016-05-24
US20120071957A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
US9345876B2 (en) Cochlear implant having electrically nonconductive occludent for tissue openings
US7962226B2 (en) Cochlear endosteal electrode carrier member
US8301269B2 (en) Implantable carrier member having a non-communicative lumen
US8180459B2 (en) Electrode assembly for a stimulating medical device
US7894916B2 (en) Insertion tool for a cochlear implant electrode array
US7881811B2 (en) Flexible electrode assembly having variable pitch electrodes
US20080082141A1 (en) Electrode assembly for a stimulating medical device
US20080269864A1 (en) Cochlear implant electrode array
EP1972359A2 (en) Securing an implanted medical device in a patient
US20070162098A1 (en) Prosthetic hearing implant electrode assembly having optimal length for atraumatic implantation
US9480838B2 (en) Cochlear electrode with apical lateral wall section and basal modiolar hugging section
US7937154B2 (en) Promoting curvature and maintaining orientation of an electrode carrier member of a stimulating medical device
US20130245569A1 (en) Accessory Device for Inner Ear Drug Delivery
US20120245534A1 (en) Drug Delivery Electrode with Temporary Fill Tube
US8447409B2 (en) Electroneural interface for a medical implant
US20050080473A1 (en) Endosteal electrode
WO2008031144A1 (en) Implantable electrode array
CN104159542B (en) Tissue stimulation electrode accessory
AU2006252212A1 (en) Improved cochleostomy sealing
US9440073B2 (en) Cochlear implant stimulation
US11426582B1 (en) Progressive insertion middle ear protector
AU2002244531B2 (en) Endosteal electrode
AU2006202622A1 (en) Endosteal electrode
AU2002244531A1 (en) Endosteal electrode

Legal Events

Date Code Title Description
AS Assignment

Owner name: COCHLEAR LIMITED, AUSTRALIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CARTER, PAUL M.;REEL/FRAME:019010/0019

Effective date: 20070129

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION